Nektar Therapeutics
NKTR
$0.8968
$0.08149.98%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 2.70% | 8.55% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.70% | 8.55% | |||
| Cost of Revenue | -54.47% | 14.13% | |||
| Gross Profit | 43.20% | 4.91% | |||
| SG&A Expenses | -7.57% | 1.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.59% | 6.92% | |||
| Operating Income | 5.99% | -5.90% | |||
| Income Before Tax | 29.19% | -42.02% | |||
| Income Tax Expenses | -80.43% | 231.43% | |||
| Earnings from Continuing Operations | 29.23% | -42.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 29.23% | -42.28% | |||
| EBIT | 5.99% | -5.90% | |||
| EBITDA | 4.91% | -6.64% | |||
| EPS Basic | 29.36% | -32.65% | |||
| Normalized Basic EPS | 5.39% | -1.48% | |||
| EPS Diluted | 29.36% | -32.65% | |||
| Normalized Diluted EPS | 5.39% | -1.48% | |||
| Average Basic Shares Outstanding | 0.20% | 7.23% | |||
| Average Diluted Shares Outstanding | 0.20% | 7.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
